Best of ASCO - 2014 Annual Meeting

 

Welcome

Adjuvant Therapy

Breast Cancer—Local/Regional/Adjuvant

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A monocentric retrospective analysis of TILs and AR as hints for prognosis definition in TNBC.

Agnese Losurdo

e12580

A prospective long term follow up of pulmonary diffusion capacity reduction caused by dose dense chemotherapy in breast cancer patients.

Yosef Landman

e12537

A prospective study on the effect of endoxifen concentration and CYP2D6 phenotypes on clinical outcome in early stage breast cancer patients receiving adjuvant tamoxifen.

Anabel Beatriz Sanchez-Spitman

523

A single centre study investigating the risk of recurrence for adjuvant hormone receptor positive breast cancer patients with mental health conditions.

Hilary Martin

e12552

ABC trial (A011502): Randomized phase III double blinded placebo controlled trial of aspirin as adjuvant therapy for breast cancer.

Wendy Y. Chen

TPS597

Absolute benefit from adjuvant chemotherapy in triple negative breast cancer (TNBC): A systemic review and meta-analysis.

Hadar Goldvaser

e12501

Absolute improvements in freedom from distant recurrence with adjuvant endocrine therapies for premenopausal women with hormone receptor-positive (HR+) HER2-negative breast cancer (BC): Results from TEXT and SOFT.

Meredith M. Regan

503

Accuracy of the prediction of the distant recurrence risk of patients with ductal luminal breast cancer based on clinical factors versus prediction based on oncogenic mutations or gene expression.

David Demanse

e12585

Adherence to hormonal therapy among commercially insured breast cancer patients.

Hui Zhao

532

Adjuvant chemotherapy for HER2-positive early breast cancer patients without perioperative radiotherapy in trastuzumab era.

Kazuki Nozawa

e12573

Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial.

Michael Gnant

500

Adjuvant denosumab in early breast cancer: First results from the international multicenter randomized phase III placebo controlled D-CARE study.

Robert E. Coleman

501

Adjuvant radiation therapy in patients with breast cancer and Li-Fraumeni syndrome: Oncologic results and incidence of second neoplasms.

Guilherme Rocha Melo Gondim

e12589

Adjuvant tamoxifen adherence in men with early stage breast cancer.

Oluchi Oke

550

Analysis of weight trends over time in female breast cancer survivors.

Damien Mikael Hansra

e12577

Antitumor effect and mechanisms research of the PARP inhibition combination with platinum salts and PI3K inhibition on human triple negative breast cancer cell.

Jin Zhang

e12535

Application of a 21-gene recurrence score assay in node negative, hormone receptor positive breast cancer in a military treatment facility.

WingYee Wan

e12567

Applying data analytics to new staging criteria.

Charlotte Cooper

e12526

Are anthracyclines needed for the neoadjuvant treatment of patients with HER2-positive early breast cancer?

Agnieszka Irena Jagiello-Gruszfeld

e12599

Assessing the effectiveness of adjuvant radiation therapy in patients with rare breast cancers including metaplastic and phyllodes tumors.

Nghia Pham

e12564

Assessment and management of bone health in women treated with adjuvant anastrozole in the DATA study.

Irene Van Hellemond

534

Assessment of long-term alopecia after adjuvant taxane therapy for early breast cancer: A cross-sectional survey.

Jennifer Wen Ying Lim

e12502

Association of a low-expression SLCO1B1 polymorphism with estrogen concentrations before and during aromatase inhibitor treatment for breast cancer.

Jacqueline M Dempsey

543

Association of breast cancer disease free survival (DFS) with omeprazole use.

Josiah An

e12544

Association of vitamin D with incidence risk of breast cancer.

Veenoo Agarwal

e12540

Associations of TP53- and/or PIK3CA mutated HR-positive, invasive ductal breast cancers (IDBC) of the METABRIC collection with distant recurrence risk (DRR) and time-to-recurrence (TTR).

Wolfgang Hackl

e12542

Balancing the risks versus benefits of trastuzumab: A call to action for oncologists, cardiologists, and cardio-oncologists.

Moira Katherine Rushton

554

Breast cancer cell-free DNA (cfDNA) profiles reflect underlying tumor biology: The Circulating Cell-Free Genome Atlas (CCGA) study.

Minetta C. Liu

536

Changes in bone mineral density with adjuvant aromatase inhibitor treatment and breast cancer recurrence.

Hilary Martin

e12596

Characteristics and treatment prognosis of 23 cases of male breast cancer.

Hongliang Wei

e12595

Circulating tumor DNA to reveal mutation profiling in relation to treatment response in different subtypes of metastatic breast cancer.

Quchang Ouyang

e12551

Comparative analysis of multigene assays (MGA) effects on chemotherapy (CT) de-escalation for women with N0, ER+ early stage breast cancer (ESBC).

Lou Hochheiser

e12519

Comparison of outcomes for AJCC 8th Anatomic and Prognostic staging in contemporary triple negative breast cancer (TNBC) multisite registry.

Rajvi H. Shah

555

Comparison of weight loss among early stage breast cancer patients post treatment: Nutrition education in combination with weight loss acupuncture vs. nutrition education alone.

Jami Aya Fukui

e12594

Comprehensive transcriptomic profiling to identify breast cancer patients that may be spared adjuvant systemic therapy.

Martin Sjostrom

535

Contributing factors of early breast cancer mortality reduction by molecular subtypes from 2000 to 2014: A single institute experience.

Shin-Cheh Chen

e12506

Cost effectiveness analysis of Oncotype DX testing in patients with synchronous unilateral primary breast cancer.

Melanie Jean Clark

e12555

Demography and survival of inflammatory breast cancer (IBC) based on histological subtypes: A hospital-based registry analysis.

Tithi Biswas

e12587

Dose tailoring of breast cancer adjuvant chemotherapy aiming at avoiding both over and undertreatment: Results from the prospective PANTHER study.

Alexios Matikas

538

Duration of extended adjuvant therapy with neratinib in early-stage HER2+ breast cancer after trastuzumab-based therapy: Exploratory analyses from the phase III ExteNET trial.

Michael Gnant

524

Early impact of a 12-week exercise intervention program on mental health, quality of life and immune markers in early stage breast cancer patients.

Joan Choo

e12571

Effect of denosumab on bone mineral density in postmenopausal Japanese women with osteopenia receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results.

Katsuhiko Nakatsukasa

e12536

Effects of antihistamine use on survival in breast cancer.

Hakan Lars Olsson

e12527

Efficacy of primary prophylactic GCSF in patients receiving docetaxel based chemotherapy for breast cancer.

Jamal M Zekri

e12516

EGFR, MUC-1 and PD-L1 expressions in cases with triple negative breast cancer (TNBC).

Semra Paydas

e12584

Elevated levels of circulating neutrophil extracellular traps and prothrombotic state after one dose of chemotherapy to predict doxorubicin cardiotoxicity in breast cancer.

Valentina K Todorova

e12579

ERCC1 and XRCC1 as prognostic biomarkers for early HER2-positive breast cancer.

E. Lubennikova

e12562

Estimation of historical control rate for a single arm de-escalation study: Application to the POSITIVE trial.

Zhuoxin Sun

552

Estrogen abrogates zoledronic acid induced gene expression signature in endocrine sensitive tumor cell lines in vitro.

Sigrid Weingartshofer

e12570

Evaluation of androgen receptor expression in pretreatment, posttreatment and recurrent breast cancer patients.

Reiki Nishimura

e12554

Evaluation of the best cut-off point for Ki-67 and progesterone receptor as a prognostic factor in hormone receptor-positive (HR+) breast cancer.

Diego Hernán Enrico

e12549

Evaluation of the OncoMasTR prognostic signature in postmenopausal women with primary ER-positive breast cancer.

Ivana Sestak

553

Evaluation of trastuzumab without chemotherapy as a postoperative adjuvant therapy in HER2-positive elderly breast cancer patients: Randomized controlled trial (RESPECT).

Masataka Sawaki

510

Factors affecting the concordance of radiologic and pathologic tumor size in breast carcinoma.

Ameer Hamza

e12568

Factors associated to treatment delay in women with primary breast cancer who were referred to reproductive specialists.

Atsuko Kitano

e12541

Four versus six cycles of docetaxel and cyclophosphamide (TC) in early stage hormone positive breast cancer.

Aparna Basu

e12576

Genomic stratification with BCI of ER+ early breast cancer patients with limited long-term risk of breast cancer death.

Virginia G. Kaklamani

516

Germline BRCA mutations (gBRCAmut) on breast cancer (BC) outcomes: A large meta-analysis.

Ruben Quek

e12575

Image-based risk score to predict recurrence of ER+ breast cancer in ECOG-ACRIN Cancer Research Group E2197.

Nishant Verma

540

Impact of high deductible insurance on out-of-pocket cost burden in breast cancer.

Christine Lu

545

Impact of number of dissected axillary lymph nodes on survival in breast cancer patients.

Ahmed M Maklad

e12593

Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: Experience of Kuwait Cancer Control Center.

Mohamed Salah Fayaz

e12582

In silico evaluation of the 12-gene molecular score (EndoPredict) and the recurrence score (Oncotype DX) as predictors of response to neo-adjuvant chemotherapy in estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer.

Hatem Hussein Soliman

539

Incidence of long-term hair loss (LHL) following docetaxel (D)-containing non-anthracycline (A) adjuvant chemotherapy (Adj) of early stage breast cancer (ESB).

John Crown

e12522

Increasing adherence to adjuvant hormone therapy among breast cancer patients: A smart phone app-based pilot study.

Jessica L. Krok-Schoen

e12523

Influence of CYP2D6 polymorphism in the outcome of breast cancer patients undergoing tamoxifen adjuvant treatment.

Isabel Blancas

e12521

Intraoperative radiation therapy (IORT) in early stage breast cancer: A first for Africa.

Yastira Ramdas

e12592

Is Oncotype DX test necessary for T1b grade 1, hormone receptor positive HER-2 negative breast cancer? A single institution retrospective analysis.

Vinay K. Gudena

e12598

Is there a role for 21-gene recurrence score in mucinous carcinoma of breast?

Kelly Khai Li Yap

e12538

Longitudinal follow-up of endothelial function in breast cancer survivors on aromatase inhibitors (AIs).

Anne Hudson Blaes

e12525

Long-term benefit from tamoxifen therapy for patients with Luminal A and Luminal B breast cancer: Retrospective analysis of the STO-3 trial.

Linda Lindström

541

Long-term outcomes in women with low-risk hormone-sensitive early-stage breast cancer.

Jinani Jayasekera

e12583

Metabolic status of BRCA1 mutation carriers.

Olga Ivanov

e12545

Molecular alterations and late recurrence in postmenopausal women with hormone receptor-positive node-positive breast cancer (BC): Results from the “SOLE” trial.

Elena Guerini Rocco

517

Molecular, biologic and clinical profiling of chromosomal instable, hormone receptor positive, invasive ductal breast cancer (IDBC).

David Demanse

e12524

National practice pattern and outcome of very early breast cancer.

Mahvish Muzaffar

e12530

Next-generation targeted sequencing (NGTS) investigating CDK4 as a prognostic driver in pure invasive lobular breast carcinoma (ILC): Preliminary results in early-stage patients (pts) stratified according to a validated clinico-pathological model.

Luisa Carbognin

542

Overall survival in female Medicare beneficiaries with early stage breast cancer receiving bisphosphonates or denosumab.

Raul A Herrera Pena

530

Patient (pt)-reported function and symptoms in APHINITY: A randomized comparison of chemotherapy (C) + trastuzumab (H) + placebo (Pla) versus C + H + pertuzumab (P) as adjuvant therapy in pts with HER2-positive early breast cancer (EBC).

Jose Baselga

521

Patient(Pt)-reported toxicities by chemotherapy regimen for early breast cancer (BC) (LCCC1334/1440).

Kirsten A. Nyrop

544

Patient(Pt)-reported toxicities during breast cancer (BC) chemotherapy (CRx): Associations with pre-treatment (Tx) measures of quality of life (QOL) and Tx discontinuation.

Kirsten A. Nyrop

546

Patterns of care and predictors of survival among DCIS patients: An NCDB analysis.

Justine Broecker

e12515

PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results.

Helena Margaret Earl

506

Persistence of circulating tumor cells in high risk early breast cancer patients five years after adjuvant chemotherapy and late recurrence: Results from the adjuvant SUCCESS A trial.

Wolfgang Janni

515

Phase II national clinical trial of prophylactic irradiation to the contralateral breast for BRCA mutation carriers treated for early breast cancer (EBC).

Ella Evron

514

Pooled analysis of two randomized phase III trials (PlanB/SuccessC) comparing six cycles of docetaxel and cyclophosphamide to sequential anthracycline taxane chemotherapy in patients with intermediate and high risk HER2-negative early breast cancer (n=5,923).

Wolfgang Janni

522

POSITIVE (IBCSG 48-14/BIG 8-13/A221405): Evaluating outcomes after interrupting endocrine therapy (ET) for women with endocrine responsive (ER+) early breast cancer (BC) who desire pregnancy.

Ann H. Partridge

TPS596

Predicting expected absolute chemotherapy treatment benefit in women with early-stage breast cancer using a 12-gene expression assay.

William John Gradishar

525

Predicting Oncotype DX scores using clinicopathologic features: A report from the National Cancer Database.

Catherine Pesce

551

Prediction of breast cancer growth rate In vivo and its clinical implications.

Shristi Bhattarai

e12581

Predictors for survival in patients with pure mucinous breast carcinoma: A retrospective analysis of 8048 cases.

Shuning Ding

e12547

PREPARE: A new clinical prognostic model for survival of Asian early breast cancer patients.

Lei Lei

e12532

Prognostic value of the detection of lympho-vascular invasion in hormone receptor positive early breast cancer in the era of molecular profiling.

Raz Mutai

e12539

Race and social status related to different health behaviors in breast cancer patients.

Kezhen Fei

e12528

Real world evaluation of effectiveness and tolerance of chemotherapy for early stage breast cancer (ESBC) in elderly women.

Glenda Maria Delgado Ramos

e12509

Real-world evidence of the effectiveness of adjuvant chemotherapy for early stage breast cancer from Scottish routine data.

Peter S Hall

e12558

Relationship between young age at diagnosis and disease free survival in premenopausal patients according to breast cancer subtypes.

Shuangshuang Lu

e12557

Relationship of axillary total tumoral load (TTL) in early breast cancer and local and distant clinical outcomes.

José E. Alés-Martínez

e12574

Report on breast cancer care (BRECC) registry at the Kenyatta National Hospital, Nairobi, Kenya.

Nicolas Anthony Othieno-Abinya

e12546

Residual risk assessment with the Breast Cancer Index (BCI) for prediction of late distant recurrence (DR) in patients from the TransATAC study.

Ivana Sestak

529

Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: The ASTRRA study.

Woo Chul Noh

502

Role of cardiac reserve as a tool to unmask cardiotoxicity following anthracycline therapy and whether exercise training can attenuate cardiotoxicity.

Steve Fraser

556

Safety and efficacy of eflapegrastim in reducing severe neutropenia in patients treated with myelosuppressive chemotherapy in a phase 3 randomized controlled trial compared to pegfilgrastim (ADVANCE trial).

Lee Steven Schwartzberg

e12513

Safety and tolerability of adjuvant enzalutamide for the treatment of early stage androgen receptor positive (AR+) triple negative breast cancer.

Tomas Lyons

531

Selection for Oncotype Dx testing among young women with early-stage ER+/HER2- breast cancer.

Philip Daniel Poorvu

533

Should radiotherapy be succeed tumorectomy in patients with low risk ductal carcinoma in situ (DCIS) when using Van Nuys Prognostic Index based treatment?

Anna Niwinska

e12561

Staging comparison on a series of 1,106 breast cancer patients, according to the 8TH VS the 7TH AJCC criteria.

Bruno Alberto Bustos

e12560

Study of clinical characteristics of breast cancer among women older than 70 years in a single institute.

Purva Sharma

e12578

Subtyping of triple-negative breast cancer (TNBC): A cohort study.

Christoph Thomssen

e12563

TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score.

Joseph A. Sparano

LBA1

Tamoxifen induced ovarian hyperstimulation during hormonal therapy for breast cancer.

Min Kyoon Kim

e12588

The Breast Cancer Weight Loss (BWEL) trial: Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early-stage breast cancer (Alliance A011401).

Jennifer A. Ligibel

TPS598

The CHANCE study: A prospective, longitudinal study of chemotherapy and hormonal therapy induced hair changes and alopecia, skin aging and nail changes in women with non-metastatic breast cancer.

Mario E. Lacouture

e12500

The clinical utility of baseline cardiac assessments prior to adjuvant anthracycline chemotherapy in breast cancer: A systematic review and meta-analysis.

Pierre O'Brien

e12505

The identification of breast cancer by Near-Infrared fluorescence imaging with methylene blue.

Chong Zhang

e12591

The impact of body composition on vertebral fractures during aromatase inhibitors therapy: A cross-sectional study.

Rebecca Pedersini

e12504

The prognostic significance of breast cancer stem cells in patients with metastatic breast cancer.

Kamel Farag

e12565

The role of histology on survival of triple negative breast cancer.

Carol Parise

e12590

Timing of initiation of neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+ hormone receptor (HR)-negative breast cancer: Exploratory analyses from the phase III ExteNET trial.

Bent Ejlertsen

549

Transcriptomic signature of tumor infiltrating lymphocytes determines prognosis in localized breast cancer.

Caroline Truntzer

e12507

Treatment and outcomes in older women with DCIS: SEER-Medicare 2007-2013.

Mary Chen Schroeder

547

Trends in triple negative breast cancer in California over 15 years.

Carol Parise

e12569

Tumor infiltrating lymphocytes to predict DFS from intense dose-dense (idd) EPC regimen: Results from the German Adjuvant Intergroup Node-positive study (GAIN-1).

Aurelia Noske

527

Two-year follow-up of pretreatment anti-mullerian hormone (AMH) to predict for resumption of mense after chemotherapy in premenopausal hormone-receptor (HR+) positive early breast cancer (eBC).

Cong Xue

e12511

UGT2B17 deletion polymorphism and exemestane-induced toxicity.

Elizabeth Packard

e12534

Urgent hypertension as a biomarker for bevacizumab in the curative setting.

Nawal Kassem

548

Using the National Cancer Data Base (NCDB) and Oncotype DX data to predict adjuvant therapy effect on overall survival (OS) of N0 & N1 breast cancer patients.

Amila Orucevic

e12529

Utility of dedicated breast positron emission tomography as a tool for predict malignancy grade and staging of breast cancer.

Norio Masumoto

e12550

Will women with breast cancer (BC) be willing to take an adjuvant CDK4/6 inhibitor in addition to endocrine therapy (ET)?

Jessica Jesin

e12566